Fount Bio selected to present its Flī-Derm™dermatology product at IMCAS

Company will present its innovative aesthetic dermatology product
in the Innovation Tank at IMCAS in Paris, February 2, 2024

CAMBRIDGE, MA  January 24, 2024 – Life sciences innovator Fount Bio, Inc., today announced it has been selected to participate in the Innovation Tank event at the IMCAS World Congress 2024, presenting its Flī-Derm™ aesthetic dermatology product. The Innovation Tank invites a select set of companies that are developing promising, new dermatology innovations the opportunity to showcase their solutions and compete for the Innovation of the Year award.

Based on Fount Bio’s proprietary Flī-HA™ bioorthogonal chemistry platform, the Flī-Derm™ product enables the building of durable forms of hyaluronic acid (HA) within the dermis via a liquid formulation that is delivered through skin micro-perforation. In a blinded clinical study, Flī-Derm™ was shown to reduce fine lines and wrinkles relative to control treatment, while demonstrating exceptional safety and tolerability.

“We are very excited to be among the select few innovators invited to participate in this premier international event for dermatology innovators,” said Fount Bio co-founder and CEO Doug Levinson, Ph.D., noting the competitive Innovation Tank selection process. “We look forward to presenting the Flī-Derm™ product, innovative Fli-HA™ technology and our product vision to the broader medical aesthetics community. Our innovation offers exciting possibilities for improving the health and well-being of patients.”

Fount Bio’s Flī-HA technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. In addition to Flī-Derm™, Fount Bio is developing a pipeline of products medical applications in the fields of  ophthalmology and gynecology.

About Fount Bio

Fount Bio is a life science company developing a pipeline of innovative products for medical   applications based on proprietary technology that combines innovations in biorthogonal chemistry and glycopolymer science. Led by an experienced management team and highly respected scientific advisors, Fount Bio combines scientific excellence, a pioneering spirit, and extensive experience in building high-value life sciences companies. The company is headquartered in Cambridge, Massachusetts, USA. Learn more at

Please direct press inquiries to or +1 (617) 249-3552